-
-
公开(公告)号：EP2521724B1
公开(公告)日：2016-11-23
申请号：EP10836790.5
申请日：2010-12-10
申请人： Nono Inc.
IPC分类号： C07D417/04 , C07D409/06 , C07D403/06 , C07D311/18 , C07D333/60 , A61K31/427 , A61K31/428 , A61P9/00 , A61P13/12 , A61P35/00
CPC分类号： A61K31/551 , A61K31/122 , A61K31/353 , A61K31/381 , A61K31/4245 , A61K31/427 , A61K31/428 , A61K31/433 , A61K31/4704 , A61K31/4709 , A61K31/4725 , A61K31/496 , C07D209/08 , C07D215/08 , C07D215/233 , C07D277/36 , C07D277/82 , C07D311/18 , C07D333/38 , C07D333/60 , C07D339/00 , C07D403/06 , C07D409/04 , C07D409/06 , C07D417/04 , C40B40/04 , G01N33/6872 , G01N2510/00
-
公开(公告)号：EP2175873A2
公开(公告)日：2010-04-21
申请号：EP08772390.4
申请日：2008-07-02
申请人： Nono, Inc. , Arbor Vita Corporation
发明人： TASKER, Andrew , DOUCETTE, Tracy , TYMIANSKI, Michael , MENDOZA, Kenneth , BELMARES, Michael, P. , GARMAN, David , LU, Peter, S.
CPC分类号： A61K38/1787 , A61K38/07
摘要： The invention provides methods of treating or effecting prophylaxis of a patient having or at risk of developing symptoms of anxiety in which an effective regime of an agent that inhibits specific binding of PSD95 to an NMDA receptor is administered to a patient.
-
-
公开(公告)号：EP2621945B1
公开(公告)日：2018-04-11
申请号：EP11833072.9
申请日：2011-09-28
申请人： NoNO Inc.
CPC分类号： C07K14/00 , A61K38/00 , C07K7/06 , C07K2319/10 , C07K2319/22 , C07K2319/23 , C12N9/0036 , C12Y106/05003
摘要： The invention is based in part on identifying a core region of ND2 responsible for interacting with Src to within residues 289-321 of ND2 and more particularly residues 307-321 or 310-321 of ND2. Peptides including, overlapping or from within this region can be used to inhibit ND2 interaction with Src Inhibition of this interaction is useful for treatment or prophylaxis of neurological diseases and disorders, pain and cancer.
-
6.发明公开MODEL SYSTEMS AND TREATMENT REGIMES FOR TREATMENT OF NEUROLOGICAL DISEASE 审中-公开模型系统和治疗可用于治疗神经系统疾病方法
公开(公告)号：EP2440230A2
公开(公告)日：2012-04-18
申请号：EP10786859.8
申请日：2010-06-10
申请人： Nono, Inc.
摘要： The invention provides animal models and clinical trials for assessing agents for potential use in treating and effecting prophylaxis stroke and other neurological diseases, particularly those mediated at least in part by excitoxitity. The invention also provides preferred dosage and infusion regimes and pharmaceutical compositions for clinical application of such agents.
-
公开(公告)号：EP2175873B1
公开(公告)日：2015-11-11
申请号：EP08772390.4
申请日：2008-07-02
申请人： NoNO Inc.
发明人： TASKER, Andrew , DOUCETTE, Tracy , TYMIANSKI, Michael , MENDOZA, Kenneth , BELMARES, Michael, P. , GARMAN, David , LU, Peter, S.
CPC分类号： A61K38/1787 , A61K38/07
-
8.发明授权
公开(公告)号：EP2229185B1
公开(公告)日：2015-10-07
申请号：EP08859906.3
申请日：2008-12-02
申请人： NoNO Inc.
IPC分类号： A61K47/42
CPC分类号： A61K38/1787 , A61K9/0019 , A61K31/56 , A61K38/08 , A61K45/06 , A61K47/645 , A61K2300/00
-
公开(公告)号：EP2723363A2
公开(公告)日：2014-04-30
申请号：EP12802409.8
申请日：2012-06-23
申请人： NoNO Inc.
发明人： TYMIANSKI, Michael
CPC分类号： A61K38/10 , A61K38/1787 , A61K38/49 , A61K2300/00
摘要： The invention provides a combination treatment for ischemia conditions in or otherwise affecting the CNS, such as stroke. The treatment involves administration of a PSD-95 inhibitor and performing reperfusion therapy (e.g., by administration of tPA). Administering a PSD-95 inhibitor in combination with reperfusion therapy increases the efficacy of the reperfusion therapy and/or slows the decline in efficacy of reperfusion therapy with time after onset of ischemia thus extending the window in which reperfusion therapy can be administered.
-
公开(公告)号：EP2720695A2
公开(公告)日：2014-04-23
申请号：EP12800164.1
申请日：2012-06-15
申请人： NoNO Inc.
发明人： SUN, Xiujun , TYMIANSKI, Michael , GARMAN, David
IPC分类号： A61K31/381 , A61K31/38 , A61K31/435 , A61P9/10 , A61P9/00
CPC分类号： C07D311/20 , C07D215/227 , C07D311/58 , C07D333/70 , C07D409/06 , C07D409/12
摘要： This invention relates to compounds that modulate TRPM7 protein activity and use of the same for treatment or prophylaxis of ischemia, cancer, pain or glaucoma.
-
-
-
-
-
-
-
-
-
搜索结果
32 条记录 (耗时 0.022 秒)
